CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
“双难治性”慢性淋巴细胞白血病患者的处理：“双重的，双重的辛劳与麻烦”（莎士比亚）
英文原题：Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare).
查看英文原题
Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
随着慢性淋巴细胞白血病患者的生存期不断延长，对于已接受多线治疗后进展的患者，显然存在未被满足的治疗需求。在本文中，我们尝试将“双重难治”患者定义为对Bruton酪氨酸激酶抑制剂（BTKi）和venetoclax均耐药，此类患者预后差，且目前尚无标准治疗方案。我们进一步探讨了对这些靶向药物耐药的机制，并讨论了当前管理该患者群体的现状。最后，我们探索了支持有前景的新药的数据，包括非共价BTKi、CAR-T 细胞以及目前正在开发中的其他类别药物。
展开英文摘要原文
As patients continue to live longer with chronic lymphocytic leukemia, it has become evident that there is an unmet treatment need for patients who have progressed on multiple lines of therapy. In this article, we attempt to define the "double refractory" patient as resistant to both Bruton's tyrosine kinase inhibitors (BTKi) and venetoclax for which prognosis is poor and there remains no standard of care.
We further examine the mechanism of resistance to these targeted agents and discuss the current landscape for managing this patient population.
Finally, we explore data supporting promising new agents, including non-covalent BTKi, chimeric antigen receptor T cells, and additional classes of agents currently in development.
论文信息
- 作者
- Aronson JH、Skånland SS、Roeker LE、Thompson MC、Mato AR
- 单位
- CLL Program, Division of Hematological Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.United States
- 文献类型
- 病例报告 · 综述 · 非美国政府资助研究
- 期刊
- American journal of hematology2022 Nov
- 原文标识
- PubMed 36125036 · DOI 10.1002/ajh.26682
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →